Microsoft word - 2006.doc

2006 Allergan Journal Publications
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a
multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I
study in healthy subjects.
Bello Carlo L; Sherman Laurie; Zhou Jihao [AGN]; Verkh Lev; Smeraglia John; Mount Janessa;
Klamerus Karen J; Allergan

Source: Anti-Cancer Drugs 2006;17(3):353-8
Utility assessment to measure the impact of dry eye disease.
Buchholz Patricia; Steeds Carolyn S; Stern Lee S; Wiederkehr Daniel P; Doyle John J; Katz Laura M;
Figueiredo Francisco C; FRCOPH; Allergan

Source: Ocul Surf 2006;4(3):155-61
Consequences of glaucoma on circadian and central visual systems
Chiquet C; Drouyer E; Woldemussie E [AGN]; Ruiz G [AGN]; Wheeler L [AGN]; Denis P; Cooper H;
Romanet JP; Allergan
Source: J Fr Ophthalmol 2006;29(7):847-851
Desiccating stress stimulates expression of matrix metalloproteinases by
the corneal epithelium
Corrales RM; Stern ME [AGN]; De Paiva CS; Welch J; Li DQ; Pflugfelder SC; Allergan
Source: Invest Ophthalmol Vis Sci 2006;47(8):3293-3302
"Yes "No" or "Yes, but"? Multinomial modelling of NICE decision-making
Dakin HA; Devlin NJ; Odeyemi IAO [AGN]; Allergan
Source: Health Policy 2006;77(3):352-367
Apical corneal barrier disruption in experimental murine dry eye is
abrogated by methylprednisolone and doxycycline
De Paiva CS; Corrales RM; Villarreal AL; Farley W; Li DQ; Stern ME [AGN]; Pflugfelder SC; Allergan
Source: Invest Ophthalmol Vis Sci 2006;47(7):2847-2856
Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine
expression, MAPK activation in the corneal epithelium in experimental dry
De Paiva CS; Corrales RM; Villarreal AL; Farley WJ; Li DQ; Stern ME [AGN]; PfLugfelder SC; Allergan
Source: Exp Eye Res 2006;83(3):526-535
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of
Streptococcus pneumoniae in rabbits in a LASIK model
Donnenfeld Robert S; Perry Henry D; Solomon Renee; Jensen Harold G [AGN]; Stein Jonathan;
Snyder Robert W; Wittpenn John R; Donnenfeld Eric D; Allergan
Source: Eye & Contact Lens 2006 Jan;32(1):46-50
Efficiency of instillation methods for prostaglandin medications. [EMBAL]
Fiscella R; Wilensky JT; Chiang TH; Walt JG [AGN]; Allergan
Source: J Ocul Pharmacol Ther 2006;22(6):477-482
Estimated comparative costs of achieving a 20% reduction in intraocular
pressure with bimatoprost or latanoprost in patients with glaucoma or
ocular hypertension
Fiscella Richard; Walt John [AGN]; Allergan
Source: Drugs Aging 2006;23(1):39-47
Costs and utilization of end-stage glaucoma patients receiving visual
rehabilitation care: A US multisite retrospective study
Gieser DK; Williams RT; O'Connell W; Pasquale LR; Rosenthal BP; Walt JG [AGN]; Katz LM; Siegartel
LR; Wang LJ; Rosenblatt LC; Stern LS; Doyle JJ; Allergan
Source: J Glaucoma 2006;15(5):419-425
Cost considerations in the medical management of glaucoma in the US:
Estimated yearly costs and cost effectiveness of bimatoprost compared
with other medications
Goldberg Lawrence D; Walt John [AGN]; Allergan
Source: PharmacoEconomics 2006;24(3):251-64
Effect of the oestrous cycle, pregnancy and uterine region on the
responsiveness of the isolated mouse uterus to prostaglandin F-2 alpha
and the thromboxane mimetic U46619
Griffiths AL; Marshall KM; Senior J; Fleming C; Woodward DF [AGN]; Allergan
Source: J Endourol 2006;188(3):569-577
The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment
of primary open angle glaucoma in five European countries.
Holmstrom Stefan [formerly AGN]; Buchholz Patricia [AGN Germany]; Walt John [AGN]; Wickstrom
Source: Curr Med Res Opin 2006;22(5):897-905
Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy) phenyl]-pyrimidine-4-
carboxamide: A potent, broad-spectrum state-dependent sodium channel
blocker for treating pain states
Ilyin VI; Pomonis JD; Whiteside GT; Harrison JE; Pearson MS; Mark L; Turchin PI; Gottshall S; Carter
RB; Nguyen P [AGN]; Hogenkamp DJ; Olanrewaju S; Benjamin E; Woodward RM; Allergan Source: J Pharmacol Exp Ther 2006;318(3):1083-1093
Pharmacokinetics and disposition of memantine in the arterially perfused
bovine eye
Koeberle MJ; Hughes PM [AGN]; Skellern GG; Wilson CG; Allergan
Source: Pharm Res 2006;23(12):2781-2798
Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F
synthase (PGFS): crystal structure of PGFS containing bimatoprost
Komoto Junichi; Yamada Taro; Watanabe Kikuko; Woodward David F [AGN]; Takusagawa Fusao;

Source: Biochemistry 2006 Feb 21;45(7):1987-1996
A multicenter, retrospective pilot study of resource use and costs
associated with severity of disease in glaucoma
Lee PP; Walt JG [AGN]; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman
RM; Jampel HD; Katz L J; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL; Allergan Source: Arch Ophthalmol 2006 Jan;124(1):12-19
A multicentre, retrospective study of resource utilization and costs
associated with glaucoma management in France and Sweden.
Lindblom Bertil; Nordmann Jean-Philippe; Sellem Eric; Chen Enping; Gold R; Polland Werner;
Williamson W; Buchholz Patricia [AGN]; Walt John G [AGN]; Groleau Danielle [AGN]; Curry Alistair; Evans Stacy

Source: Acta Ophthalmologica Scandinavica 2006;84(1):74-83
Changes in endocannabinoid and palmitoylethanolamide levels in eye
tissues of patients with diabetic retinopathy and age-related macular
Matias I; Wang JW [AGN]; Morriello AS; Nieves A [AGN]; Woodward DF [AGN]; Di Marzo V; Allergan
Source: Prostaglandins Leukot Essent Fatty Acids 2006;75(6):413-418
Comparative toxicity of fluoroquinolone antibiotics on corneal cells in vitro.
Matsumoto Steven [AGN]; Way William [AGN]; Tarlo Kirk [AGN]; Short Brian [AGN]; Allergan
Source: Cornea 2006;25(9 Suppl 2):S1-S7
Categorizing the stage of glaucoma from pre-diagnosis to end-stage
Mills RP; Budenz DL; Lee PP; Noecker RJ; Walt JG [AGN]; Siegartel LR; Evans SJ; Doyle JJ; Allergan
Source: Am J Ophthalmol 2006 Jan;141(1):24-30
Altered expression of neurotransmitter receptors and neuromediators in
vernal keratoconjunctivitis
Motterle L; Diebold Y; de Salamanca AE; Saez V; Garcia-Vazquez C; Stern ME [AGN]; Calonge M;
Leonardi A; Allergan
Source: Arch Ophthalmol 2006;124(4):462-468
Desiccating stress induces T cell-mediated Sjogren's syndrome-like
lacrimal keratoconjunctivitis
Niederkorn JY; Stern ME [AGN]; Pflugfelder SC; De Paiva CS; Corrales RM; Gao J [AGN]; Siemasko K
[AGN]; Allergan
Source: Immunology 2006 Jan;176:3950-3957
The prostanoid EP2 receptor agonist butaprost increases uveoscleral
outflow in the cynomolgus monkey
Nilsson SFE; Drecoll E; Lutjen-Drecoll E; Toris CB; Krauss AHP [AGN]; Kharlamb A [AGN]; Nieves A
[AGN]; Guerra T [AGN]; Woodward DF [AGN]; Allergan
Source: Invest Ophthalmol Vis Sci 2006;47(9):4042-4049
Cost-effectiveness of monotherapy treatment of glaucoma and ocular
hypertension with the lipid class of medications
Noecker RJ; Walt JG [AGN]; Allergan
Source: Am J Ophthalmol 2006 Jan;141(1):S15-S21
Protection of RPE cells from oxidative injury by 15-deoxy-delta12,14-
prostaglandin J2 by augmenting GSH and activating MAPK.
Qin Suofu [AGN]; McLaughlin Anne P [AGN]; De Vries Gerald W [AGN]; Allergan
Source: Invest Ophthalmol Vis Sci 2006;47(11):5098-105
Carbohydrate-based micelle clusters which enhance hydrophobic drug
bioavailability by up to 1 order of magnitude
Qu XZ; Khutoryanskiy VV; Stewart A; Rahman S; Papahadjopoulos-Sternberg B; Dufes C; McCarthy
D; Wilson CG; Lyons R [AGN]; Carter KC; Schatzlein A; Uchegbu IF; Allergan Source: Biomacromolecules 2006;7(12):3452-3459
N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal
pigment epithelial cells: Retinoic acid receptors regulate apoptosis,
reactive oxygen species generation, and the expression of heme
oxygenase-1 and Gadd153
Samuel W; Kutty RK; Nagineni S; Vijayasarathy C; Chandraratna RAS [AGN]; Wiggert B; Allergan
Source: J Cell Physiol 2006;209(3):854-865
Twice-daily 0.2% brimonidine 0.5% timolol fixed-combination therapy vs
monotherapy with timolol or brimonidine in patients with glaucoma or
ocular hypertension. A 12-month randomized trial
Sherwood MB; Craven ER; Chou C [AGN]; DuBiner HB; Batoosingh AL [AGN]; Schiffman RM [AGN];
Whitcup SM [AGN]; Combigan Study Groups I and II; Allergan Source: Arch Ophthalmol 2006;124(9):1230-1238
Evaluation of quality of life for patients with glaucoma
Spaeth G; Walt J [AGN]; Keener J; Allergan
Source: Am J Ophthalmol 2006;141:S3-S14
Effects of fourth-generation fluoroquinolones on the ocular surface,
epithelium, and wound healing.
Stern ME [AGN]; Gao J [AGN]; Beuerman RW; Farley W; Zhuo L; McDonnell PJ; Pflugfelder SC;

Source: Cornea 2006;25(9 SUPPL.2):S12-S24
Evoked expression of the glutamate transporter GLT-1c in retinal ganglion
cells in human glaucoma and in a rat model
Sullivan RKP; WoldeMussie E [AGN]; Macnab L; Ruiz G [AGN]; Pow DV; Allergan
Source: Invest Ophthalmol Vis Sci 2006;47(9):3853-3859
Ocular changes after photodynamic therapy
Tzekov Radouil [AGN]; Lin Ton [AGN]; Zhang Kai-Ming [AGN]; Jackson Brittany [AGN]; Oyejide
Adelekan [AGN]; Orilla Werhner [AGN]; Kulkarni Amol D [AGN]; Kuppermann Baruch D; Wheeler Larry [AGN]; Burke James [AGN]; Allergan Source: Invest Ophthalmol Vis Sci 2006 Jan;47(1):377-85
Recent advances in ocular therapeutics
Whitcup Scott M [AGN]; Allergan
Source: Int Ophthalmol Clin 2006;46(4):1-6
Measurement of persistence and adherence to regimens of IOP-lowering
glaucoma medications using pharmacy claims data
Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J [AGN]; Allergan
Source: Am J Ophthalmol 2006;141(1 SUPPL):S28-S33
Potential antinociceptive mechanisms of botulinum toxin. MOGLICHE
Aoki KR [AGN]; Francis J [AGN]; Jost WH; Allergan
Source: Schmerz 2006 Sep;20(5):381-7
Using translational medicine to understand clinical differences between
botulinum toxin formulations
Aoki KR [AGN]; Ranoux D; Wissel J; Allergan
Source: Eur J Neurol 2006;13(Suppl 4):10-19
Understanding the role of botulinum toxin A in the treatment of the
overactive bladder-more than just muscle relaxation
Apostolidis A; Haferkamp A; Aoki KR [AGN]; Allergan
Source: Eur Urol Suppl 2006;5(11):670-678
The impact of the overactive bladder on health-related utility and quality of
Currie CJ; McEwan P; Poole CD; Odeyemi IAO [AGN]; Datta SN; Morgan CL; Allergan
Source: BJU Int 2006;97(6):1267-1272
The structure and mode of action of different botulinum toxins
Dolly JO; Aoki KR [AGN]; Allergan
Source: Eur J Neurol 2006;13(Suppl 4):1-9
A series of three sequential, randomized, controlled studies of repeated
treatments with botulinum toxin type A for migraine prophylaxis
Elkind Arthur H; O'Carroll Philip; Blumenfeld Andrew; DeGryse Ronald [AGN]; Dimitrova Rozalina
[AGN]; BoNTA-024-026-036 Study Group; Allergan
Source: J Pain 2006;7(10):688-696
Botulinum neurotoxin: From laboratory to bedside
Foster KA; Bigalke H; Aoki KR [AGN]; Allergan
Source: Neurotox Res 2006 Apr;9(2-3):133-140
Effectiveness of repeated treatment with botulinum toxin type A across
different conditions
Gordon MF; Barron R [AGN]; Allergan
Source: South Med J 2006;99(8):853-861
Primary focal hyperhidrosis: Disease characteristics and functional
Hamm H; Naumann MK; Kowalski JW [AGN]; Kutt S; Kozma C; Teale C [AGN]; Allergan
Source: Dermatology 2006;212(4):343-353
Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in
patients with detrusor overactivity based on clinical outcomes observed at
a single UK centre
Kalsi V; Popat RB; Apostolidis A; Kavia R; Odeyemi IA [AGN]; Dakin HA; Warner J; Elneil S; Fowler
CJ; Dasgupta P; Allergan
Source: Eur Urol 2006 Mar;49(3):519-27
Two protein trafficking processes at motor nerve endings unveiled by
botulinum neurotoxin E
Lawrence G; Wang J; Kwo Chion CKN; Aoki RK [AGN]; Dolly OJ; Allergan
Source: J Pharmacol Exp Ther 2006;320(1):410-18
Inhibition by human sera of botulinum neurotoxin-A binding to
synaptosomes: A new assay for blocking and non-blocking antibodies
Maruta T; Dolimbek BZ; Aoki KR [AGN]; Atassi MZ; Allergan
Source: J Neurosci Methods 2006;151(2):90-96
Epidemiology, prescribing patterns and resource use associated with
overactive bladder in UK primary care
Odeyemi AO [AGN]; Dakin HA; O'Donnel RA; Warner J; Jacobs A; Dasgupta P; Allergan
Source: Int J Clin Pract 2006 Aug;60(8):949-58
Botulinum toxin type A in the prophylactic treatment of chronic tension-
type headache: A multicentre, double-blind, randomized, placebo-
controlled, parallel-group study
Silberstein SD; Gobel H; Jensen R; Elkind AH; DeGryse R [AGN]; Walcott JMCM [AGN]; Turkel C
[AGN]; Allergan

Source: Cephalalgia 2006;26(7):790-800
Developing patient-reported outcome measures for pain clinical trials:
IMMPACT recommendations
Turk DC; Dworkin RH; Burke LB; Gershon R; Rothman M; Scott J; Allen RR; Atkinson JH; Chandler J;
Cleeland C; Cowan P; Dimitrova R [AGN]; Dionne R; Farrar JT; Haythornthwaite JA; Hertz S; Jadad AR; Jensen

MP; Kellstein D; Kerns RD; Manning DC; Martin S; Max MB; McDermott MP; McGrath P; Moulin DE; Nurmikko T; Quessy S; Raja S; Rappaport BA; Rauschkolb C; Robinson JP; Royal MA; Simon L; Stauffer JW; Stucki G; Tollett J; von Stein T; Wallace MS; Wernicke J; White RE; Williams AC; Witter J; Wyrwich KW; Allergan
Source: Pain 2006;125(3):208-215
Pooled analysis of the safety of botulinum toxin type A in the treatment of
poststroke spasticity
Turkel Catherine C [AGN]; Bowen Beta [AGN]; Liu Jingyu [AGN]; Brin Mitchell F [AGN]; Allergan
Source: Arch Phys Med Rehabil 2006 Jun;87(6):786-92


Stan Douglas Born 1960, Vancouver. Lives and works in Vancouver, British Columbia, Canada. EDUCATION 1982 Emily Carr College of Art, Vancouver, British Columbia, Canada SOLO EXHIBITIONS 2009 Stan Douglas: Klatsassin , Mongin Art Center, Seoul, Korea [brochure] Stan Douglas: Klatsassin , Vancouver Art Gallery, Vancouver, British Columbia, Canada 2008 Stan Douglas: Humor, Irony a

Microsoft word - haldol 08-2011.doc

The medication Haldol is a typical neuroleptic. It is used to treat psychosis. Psychosis can be experienced as disorganized thinking or behavior and unusual perceptions (hearing voices, seeing things, feeling paranoid). Haldol is also used to treat other clinical situations such as tics and stuttering or extreme mood instability. Generally these symptoms interfere with your life goals. Hald

Copyright ©2010-2018 Medical Science